Comparative effectiveness and safety of biologics and targeted small-molecule therapies plus stable background therapy in systemic lupus erythematosus: a systematic review and network meta-analysis - Summary - MDSpire
Advertisement
Comparative effectiveness and safety of biologics and targeted small-molecule therapies plus stable background therapy in systemic lupus erythematosus: a systematic review and network meta-analysis
To compare the efficacy and safety of biologics and targeted small molecule drugs combined with stable background therapy for systemic lupus erythematosus (SLE).
Key Findings:
Telitacicept was superior to Belimumab for SRI-4 response, indicating its potential as a preferred treatment option.
Ustekinumab outperformed Epratuzumab, suggesting its effectiveness in SLE management.
Upadacitinib showed superior efficacy compared to Baricitinib for BICLA response and LLDAS attainment, highlighting its therapeutic advantages.
Deucravacitinib and Anifrolumab were more effective for CLASI-50 achievement than Baricitinib, emphasizing their role in cutaneous manifestations.
Anifrolumab, Iberdomide, and Telitacicept had a higher incidence of adverse events, necessitating careful monitoring.
Cenerimod had the lowest risk of serious adverse events, while IL-2 showed the lowest risk of infection-related adverse events, indicating a safer profile.
Interpretation:
The findings suggest that certain biologics and targeted therapies have favorable efficacy and safety profiles in treating SLE, particularly for specific outcomes like SRI-4 and CLASI-50, which may influence treatment decisions.
Limitations:
Long-term efficacy and safety of the treatments require further investigation, particularly in diverse patient populations.
The study may have limitations related to the heterogeneity of included trials, which could affect the generalizability of the results.
Conclusion:
Telitacicept and Ustekinumab demonstrated superior efficacy for SRI-4 response; Upadacitinib was superior for BICLA response and LLDAS achievement, indicating therapeutic potential for SLE with cutaneous manifestations. Further research is essential to validate these findings.
While most CAR T-cell therapies and clinical trials are directed at cancers, a new phase 1 trial at Roswell Park Comprehensive Cancer Center is open and recruiting patients with a variety of autoimmune conditions.
